Evidence map›Paper›PMID 19388114›Full record

ArticleJournal of magnetic resonance imaging : JMRI2009

MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.

S O Aliu, L J Wilmes, M M Moasser, B C Hann, K-L Li, D Wang, N M Hylton

Open access · bronzeAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Assessment of tumor response to tyrosine kinase inhibitors.Frontiers in bioscience (Landmark edition) · 2011
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

S O AliuDepartment of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, California 94107, USA. sheye.aliu@radiology.ucsf.edu
L J Wilmes
M M Moasser
B C Hann
K-L Li
D Wang
N M Hylton
University of California, San Francisco · USUCSF Helen Diller Family Comprehensive Cancer Center · USGraduate Theological Union · US

Funding

ANATOMIC AND BIOLOGIC STAGING OF BREAST DISEASE WITH MRIR01CA069587 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M. · 1997 to 2010
$3.5M
Understanding resistance to HER family tyrosine kinase inhibitorsR01CA122216 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOASSER, MARK M · 2007 to 2017
$3.0M
NCI NIH HHS R01 CA059487NCI NIH HHS R01 CA069587NCI NIH HHS R01 CA122216
6 · The paper itself

Abstract

purposeTo evaluate whether quantitative MRI parameters are sensitive to the effects of the tyrosine kinase inhibitor gefitinib and can discriminate between two different treatment protocols. MATERIALS AND

methodsUntreated mice with BT474 breast tumor xenografts were characterized in a preliminary study. Subsequently, tumor volume, apparent diffusion coefficient (ADC), transendothelial permeability (K(ps)), and fractional plasma volume (fPV) were measured in three groups of mice receiving: 1) control vehicle for 10 days, or gefitinib as 2) a single daily dose for 10 days or 3) a 2-day pulsed dose.

resultsGefitinib treatment resulted in significant tumor growth inhibition (pulsed: 439 +/- 93; daily: 404 +/- 53; control: 891 +/- 174 mm(3), P < 0.050) and lower cell density (pulsed: 0.15 +/- 0.01, daily: 0.17 +/- 0.01, control: 0.24 +/- 0.01, P < 0.050) after 9 days. Tumor ADC increased in treated groups but decreased in controls (P > 0.050). Tumor K(ps) decreased with pulsed treatment but rebounded afterwards and increased with daily treatment (P > 0.050). Tumor fPV increased in both treated groups, decreasing afterwards with pulsed treatment (P > 0.050).

conclusionQuantitative MRI can provide a sensitive measure of gefitinib-induced tumor changes, potentially distinguish between treatment regimens, and may be useful for determining optimal treatment scheduling for enhancing chemotherapy delivery.

Indexed as

Disease Models, AnimalAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorDose-Response Relationship, DrugDrug Administration ScheduleFemaleGefitinibHumansMagnetic Resonance ImagingMiceMice, NudeOutcome Assessment, Health CarePrognosisProtein Kinase InhibitorsAntineoplastic AgentsGefitinibProtein Kinase InhibitorsProtein-Tyrosine KinasesQuinazolines

Identifiers

PMID19388114
PMCPMC4511711
OpenAlexW2001416445

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.